Over the last 20 years, MedsPharma has established a worldwide reputation for delivering exceptional solutions for our clients. We help them to navigate the complexities of topical and trans-dermal product development, ensuring they are taking the most effective formulation to the clinic.

From its roots at King’s College London, MedsPharma has grown into a thriving organisation with facilities in Guildford, UK, USA, Durham and North Carolina. Providing services from API to clinical batch supply, MedsPharma is a well-established, and world-renowned contract research organisation specialising in dermatological, nail, eye, airway, mucosal membrane and transdermal product development. 

Clients from all over the globe have been successful using formulation development programmes that are based on our pillars of scientific integrity, innovation and rigor. The vast formulation and product development experience, offered by MedsPharma’s experts, has contributed to the development and approval of 55 marketed products for clients around the globe, including the US, Europe and Japan.

MedsPharma supports clients in mitigating development risks, creating data packages more likely to attract investors and support submissions that inspire regulators’ confidence. We leverage our 20 years of industry experience to provide innovative and trusted guidance to clients, so their programmes have the best chance of success.

Pioneering research is fundamental to what we do here at MedsPharma. With highly automated processes and proprietary technology, we are changing the way our industry looks at topical formulation development.  

This approach to projects means that we are constantly looking for opportunities to develop new formulation and drug delivery technologies. These proprietary tools, such as MedSpray®, enhance clients’ products, provide clinical benefits for patients and meet the increasingly stringent requirements of regulatory authorities.

MedsPharma was the first company to achieve European approval of topical generic products with in vitro bioequivalence testing only.

Proprietary performance testing models allows MedsPharma to enhance the clinical efficacy of our clients’ compounds.